emmanuelle Charafe-Jauffret

List of Publications by Year
in descending order

107 papers	15,056 citations	36203 51 h-index	22102 113 g-index
124 all docs	124 docs citations	124 times ranked	18013 citing authors

#	Article	IF	Citations
1	ALDH1 Is a Marker of Normal and Malignant Human Mammary Stem Cells and a Predictor of Poor Clinical Outcome. Cell Stem Cell, 2007, 1, 555-567.	5.2	3,550
2	Breast Cancer Cell Lines Contain Functional Cancer Stem Cells with Metastatic Capacity and a Distinct Molecular Signature. Cancer Research, 2009, 69, 1302-1313.	0.4	1,067
3	Breast Cancer Stem Cells Transition between Epithelial and Mesenchymal States Reflective of their Normal Counterparts. Stem Cell Reports, 2014, 2, 78-91.	2.3	854
4	CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. Journal of Clinical Investigation, 2010, 120, 485-497.	3.9	658
5	Aldehyde Dehydrogenase 1â€“Positive Cancer Stem Cells Mediate Metastasis and Poor Clinical Outcome in Inflammatory Breast Cancer. Clinical Cancer Research, 2010, 16, 45-55.	3.2	646
6	Regulation of Mammary Stem/Progenitor Cells by PTEN/Akt/Î²-Catenin Signaling. PLoS Biology, 2009, 7, e1000121.	2.6	484
7	Salinomycin kills cancer stem cells by sequestering iron in lysosomes. Nature Chemistry, 2017, 9, 1025-1033.	6.6	423
8	BRCA1 regulates human mammary stem/progenitor cell fate. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 1680-1685.	3.3	417
9	Gene expression profiling of colon cancer by DNA microarrays and correlation with histoclinical parameters. Oncogene, 2004, 23, 1377-1391.	2.6	293
10	Gene Expression Profiling Shows Medullary Breast Cancer Is a Subgroup of Basal Breast Cancers. Cancer Research, 2006, 66, 4636-4644.	0.4	273
11	Integrated Profiling of Basal and Luminal Breast Cancers. Cancer Research, 2007, 67, 11565-11575.	0.4	254
12	Gene Expression Profiling Identifies Molecular Subtypes of Inflammatory Breast Cancer. Cancer Research, 2005, 65, 2170-2178.	0.4	229
13	Comprehensive Profiling of 8p11-12 Amplification in Breast Cancer. Molecular Cancer Research, 2005, 3, 655-667.	1.5	201
14	Typical medullary breast carcinomas have a basal/myoepithelial phenotype. Journal of Pathology, 2005, 207, 260-268.	2.1	198
15	Retinoid signaling regulates breast cancer stem cell differentiation. Cell Cycle, 2009, 8, 3297-3302.	1.3	193
16	Immunophenotypic analysis of inflammatory breast cancers: identification of anâ€˜inflammatory signatureâ€™. Journal of Pathology, 2004, 202, 265-273.	2.1	180
17	Gene Expression Profiling for Molecular Characterization of Inflammatory Breast Cancer and Prediction of Response to Chemotherapy. Cancer Research, 2004, 64, 8558-8565.	0.4	177
18	WNT pathway and mammary carcinogenesis: Loss of expression of candidate tumor suppressor gene SFRP1 in most invasive carcinomas except of the medullary type. Oncogene, 2001, 20, 5810-5817.	2.6	169

#	Article	IF	Citations
19	Cancer Stem Cells in Breast: Current Opinion and Future Challenges. Pathobiology, 2008, 75, 75-84.	1.9	169
20	Circulating tumour cells from patients with colorectal cancer have cancer stem cell hallmarks inex vivoculture. Gut, 2017, 66, 1802-1810.	6.1	163
21	Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study. Lancet Oncology, The, 2012, 13, 375-384.	5.1	160
22	MicroRNA93 Regulates Proliferation and Differentiation of Normal and Malignant Breast Stem Cells. PLoS Genetics, 2012, 8, e1002751.	1.5	150
23	Protein expression profiling identifies subclasses of breast cancer and predicts prognosis. Cancer Research, 2005, 65, 767-79.	0.4	148
24	Distinct and Complementary Information Provided by Use of Tissue and DNA Microarrays in the Study of Breast Tumor Markers. American Journal of Pathology, 2002, 161, 1223-1233.	1.9	144
25	Poor prognosis in breast carcinomas correlates with increased expression of targetable CD146 and c-Met and with proteomic basal-like phenotype. Human Pathology, 2007, 38, 830-841.	1.1	142
26	Genome profiling of ERBB2-amplified breast cancers. BMC Cancer, 2010, 10, 539.	1.1	136
27	Nectin-4 is a new histological and serological tumor associated marker for breast cancer. BMC Cancer, 2007, 7, 73.	1.1	134
28	CD44 regulates epigenetic plasticity by mediating iron endocytosis. Nature Chemistry, 2020, 12, 929-938.	6.6	132
29	A stemness-related ZEB1â€“MSRB3 axis governs cellular pliancy and breast cancer genome stability. Nature Medicine, 2017, 23, 568-578.	15.2	131
30	ZNF703 gene amplification at 8p12 specifies luminal B breast cancer. EMBO Molecular Medicine, 2011, 3, 153-166.	3.3	126
31	The Histone Deacetylase Inhibitor Abexinostat Induces Cancer Stem Cells Differentiation in Breast Cancer with Low Xist Expression. Clinical Cancer Research, 2013, 19, 6520-6531.	3.2	122
32	Prognosis and Gene Expression Profiling of 20q13-Amplified Breast Cancers. Clinical Cancer Research, 2006, 12, 4533-4544.	3.2	121
33	Frequency, prognostic impact, and subtype association of 8p12, 8q24, 11q13, 12p13, 17q12, and 20q13 amplifications in breast cancers. BMC Cancer, 2006, 6, 245.	1.1	120
34	Mevalonate Metabolism Regulates Basal Breast Cancer Stem Cells and Is a Potential Therapeutic Target. Stem Cells, 2012, 30, 1327-1337.	1.4	120
35	Differential expression assay of chromosome arm 8p genes identifies Frizzled-related (FRP1/FRZB) and Fibroblast Growth Factor Receptor 1 (FGFR1) as candidate breast cancer genes. Oncogene, 1999, 18, 1903-1910.	2.6	118
36	Identification and validation of an ERBB2 gene expression signature in breast cancers. Oncogene, 2004, 23, 2564-2575.	2.6	117

#	Article	IF	Citations
37	miR-600 Acts as a Bimodal Switch that Regulates Breast Cancer Stem Cell Fate through WNT Signaling. Cell Reports, 2017, 18, 2256-2268.	2.9	111
38	Sixteenâ€“Kinase Gene Expression Identifies Luminal Breast Cancers with Poor Prognosis. Cancer Research, 2008, 68, 767-776.	0.4	105
39	Breast cancer stem cells: tools and models to rely on. BMC Cancer, 2009, 9, 202.	1.1	105
40	ALDH1-Positive Cancer Stem Cells Predict Engraftment of Primary Breast Tumors and Are Governed by a Common Stem Cell Program. Cancer Research, 2013, 73, 7290-7300.	0.4	103
41	Identification of p62/SQSTM1 as a component of non-canonical Wnt VANGL2â€“JNK signalling in breast cancer. Nature Communications, 2016, 7, 10318.	5.8	85
42	High expression of indoleamine 2,3â€dioxygenase in the tumour is associated with medullary features and favourable outcome in basalâ€like breast carcinoma. International Journal of Cancer, 2012, 130, 96-104.	2.3	77
43	Protein Profiling of Human Breast Tumor Cells Identifies Novel Biomarkers Associated with Molecular Subtypes. Molecular and Cellular Proteomics, 2008, 7, 1420-1433.	2.5	74
44	Association of GATA3, P53, Ki67 status and vascular peritumoral invasion are strongly prognostic in luminal breast cancer. Breast Cancer Research, 2009, 11, R23.	2.2	74
45	Carcinogenesis and translational controls: TACC1 is down-regulated in human cancers and associates with mRNA regulators. Oncogene, 2002, 21, 5619-5630.	2.6	73
46	Moesin expression is a marker of basal breast carcinomas. International Journal of Cancer, 2007, 121, 1779-1785.	2.3	70
47	Comparative genomic analysis of primary tumors and metastases in breast cancer. Oncotarget, 2016, 7, 27208-27219.	0.8	69
48	Comparative multi-methodological measurement of ERBB2 status in breast cancer. Journal of Pathology, 2004, 202, 286-298.	2.1	61
49	Chromosome arm 8p and cancer: a fragile hypothesis. Lancet Oncology, The, 2003, 4, 639-642.	5.1	57
50	High-Resolution Comparative Genomic Hybridization of Inflammatory Breast Cancer and Identification of Candidate Genes. PLoS ONE, 2011, 6, e16950.	1.1	57
51	Pathological Response and Circulating Tumor Cell Count Identifies Treated HER2+ Inflammatory Breast Cancer Patients with Excellent Prognosis: BEVERLY-2 Survival Data. Clinical Cancer Research, 2015, 21, 1298-1304.	3.2	56
52	Candidate Luminal B Breast Cancer Genes Identified by Genome, Gene Expression and DNA Methylation Profiling. PLoS ONE, 2014, 9, e81843.	1.1	53
53	Defining the Molecular Biology of Inflammatory Breast Cancer. Seminars in Oncology, 2008, 35, 41-50.	0.8	52
54	How different are luminal A and basal breast cancers?. International Journal of Cancer, 2009, 124, 1338-1348.	2.3	51

#	Article	IF	Citations
55	Poly(ADP-Ribose) Polymerase 1 (PARP1) Overexpression in Human Breast Cancer Stem Cells and Resistance to Olaparib. PLoS ONE, 2014, 9, e104302.	1.1	43
56	Bevacizumab plus neoadjuvant chemotherapy in patients with HER2-negative inflammatory breast cancer (BEVERLY-1): a multicentre, single-arm, phase 2 study. Lancet Oncology, The, 2016, 17, 600-611.	5.1	43
57	Constitutive nuclear localization and initial cytoplasmic apoptotic activation of endogenous caspase-3 evidenced by confocal microscopy. International Journal of Experimental Pathology, 2003, 84, 75-81.	0.6	34
58	8q24 Cancer Risk Allele Associated with Major Metastatic Risk in Inflammatory Breast Cancer. PLoS ONE, 2012, 7, e37943.	1.1	34
59	Brief Reports: A Distinct DNA Methylation Signature Defines Breast Cancer Stem Cells and Predicts Cancer Outcome. Stem Cells, 2014, 32, 3031-3036.	1.4	33
60	Phenotypic discordance between primary and metastatic breast cancer in the large-scale real-life multicenter French ESME cohort. Npj Breast Cancer, 2021, 7, 41.	2.3	33
61	Markers of subtypes in inflammatory breast cancer studied by immunohistochemistry: Prominent expression of P-cadherin. BMC Cancer, 2008, 8, 28.	1.1	32
62	Depleting MET-Expressing Tumor Cells by ADCC Provides a Therapeutic Advantage over Inhibiting HGF/MET Signaling. Cancer Research, 2015, 75, 3373-3383.	0.4	32
63	CD95/Fas and metastatic disease: What does not kill you makes you stronger. Seminars in Cancer Biology, 2020, 60, 121-131.	4.3	31
64	Reciprocal translocations in breast tumor cell lines: Cloning of a t(3;20) that targets theFHITgene. Genes Chromosomes and Cancer, 2002, 35, 204-218.	1.5	30
65	ETV6 gene rearrangements in invasive breast carcinoma. Genes Chromosomes and Cancer, 2005, 44, 103-108.	1.5	30
66	A genomeâ€wide <scp>RNA</scp> i screen reveals essential therapeutic targets of breast cancer stem cells. EMBO Molecular Medicine, 2019, 11, e9930.	3.3	27
67	MARCKS protein overexpression in inflammatory breast cancer. Oncotarget, 2017, 8, 6246-6257.	0.8	27
68	Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC - PACS 01 randomized trial. Breast Cancer Research, 2011, 13, R109.	2.2	24
69	Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial. Genome Medicine, 2021, 13, 87.	3.6	24
70	Absence of ESR1 amplification in a series of breast cancers. International Journal of Cancer, 2008, 123, 2970-2972.	2.3	23
71	PH-domain-binding inhibitors of nucleotide exchange factor BRAG2 disrupt Arf GTPase signaling. Nature Chemical Biology, 2019, 15, 358-366.	3.9	22
72	XIST loss impairs mammary stem cell differentiation and increases tumorigenicity through Mediator hyperactivation. Cell, 2022, 185, 2164-2183.e25.	13.5	22

#	Article	IF	Citations
73	p53 and cancer stem cells: The mevalonate connexion. Cell Cycle, 2012, 11, 2583-2584.	1.3	21
74	Loss of FHIT protein expression is a marker of adverse evolution in good prognosis localized breast cancer. International Journal of Cancer, 2003, 107, 854-862.	2.3	19
75	The SCRIB Paralog LANO/LRRC1 Regulates Breast Cancer Stem Cell Fate through WNT/Î²-Catenin Signaling. Stem Cell Reports, 2018, 11, 1040-1050.	2.3	18
76	How to best classify breast cancer: Conventional and novel classifications (Review). International Journal of Oncology, 2005, 27, 1307.	1.4	17
77	Development of parallel reaction monitoring (PRM)-based quantitative proteomics applied to HER2-Positive breast cancer. Oncotarget, 2018, 9, 33762-33777.	0.8	17
78	CD95/Fas suppresses NF-ÎºB activation through recruitment of KPC2 in a CD95L/FasL-independent mechanism. IScience, 2021, 24, 103538.	1.9	16
79	Basal and luminal breast cancers: basic or luminous? (review). International Journal of Oncology, 2004, 25, 249-58.	1.4	16
80	Inflammatory breast cancers in Tunisia and France show similar immunophenotypes. Breast, 2007, 16, 352-358.	0.9	15
81	Modeling Heterogeneity of Tripleâ€Negative Breast Cancer Uncovers a Novel Combinatorial Treatment Overcoming Primary Drug Resistance. Advanced Science, 2021, 8, 2003049.	5.6	15
82	A stem cell population at the anorectal junction maintains homeostasis and participates in tissue regeneration. Nature Communications, 2021, 12, 2761.	5.8	15
83	BMI1 nuclear location is critical for RAD51-dependent response to replication stress and drives chemoresistance in breast cancer stem cells. Cell Death and Disease, 2022, 13, 96.	2.7	13
84	Overcoming Resistance to Antiâ€“Nectin-4 Antibody-Drug Conjugate. Molecular Cancer Therapeutics, 2022, 21, 1227-1235.	1.9	13
85	Prognostic marker profile to assess risk in stage Iâ€“III hormone receptorâ€positive breast cancer patients. International Journal of Cancer, 2009, 124, 896-904.	2.3	12
86	Targeting breast cancer stem cells: fishing season open!. Breast Cancer Research, 2010, 12, 312.	2.2	11
87	Consistency in recognizing microinvasion in breast carcinomas is improved by immunohistochemistry for myoepithelial markers. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2016, 468, 473-481.	1.4	11
88	Targeted NGS, array-CGH, and patient-derived tumor xenografts for precision medicine in advanced breast cancer: a single-center prospective study. Oncotarget, 2016, 7, 79428-79441.	0.8	11
89	The Evolution and Prognostic Role of Tumour-Infiltrating Lymphocytes and Peripheral Blood-Based Biomarkers in Inflammatory Breast Cancer Patients Treated with Neoadjuvant Chemotherapy. Cancers, 2021, 13, 4656.	1.7	10
90	How to best classify breast cancer: conventional and novel classifications (review). International Journal of Oncology, 2005, 27, 1307-13.	1.4	9

#	Article	IF	Citations
91	Loss of heterozygosity at microsatellite markers from region p11-21 of chromosome 8 in microdissected breast tumor but not in peritumoral cells. International Journal of Oncology, 2002, 21, 989.	1.4	7
92	Breast tumor microenvironment: In the eye of the cytokine storm. Cell Cycle, 2011, 10, 2421-2421.	1.3	7
93	Transcriptomic Analysis of Breast Cancer Stem Cells and Development of a pALDH1A1:mNeptune Reporter System for Live Tracking. Proteomics, 2019, 19, e1800454.	1.3	7
94	Docetaxel first-line therapy in HER2-negative advanced breast cancer: a cohort study in patients with prospectively determined HER2 status. Anti-Cancer Drugs, 2009, 20, 946-952.	0.7	6
95	Prognostic impact of hormone receptor- and HER2-defined subtypes in inflammatory breast cancer treated with high-dose chemotherapy: a retrospective study. Journal of Cancer, 2016, 7, 2077-2084.	1.2	6
96	Breast cancer stem cells programs: enter the (non)-code. Briefings in Functional Genomics, 2016, 15, 186-199.	1.3	6
97	Quantification of Immune Variables from Liquid Biopsy in Breast Cancer Patients Links VÎ´2+ Î³Î´ T Cell Alterations with Lymph Node Invasion. Cancers, 2021, 13, 441.	1.7	6
98	Invasive ductal breast carcinoma with predominant intraductal component: Clinicopathological features and prognosis. Breast, 2016, 27, 8-14.	0.9	5
99	Immunohistochemical subtypes predict survival in metastatic breast cancer receiving high-dose chemotherapy with autologous haematopoietic stem cell transplantation. European Journal of Cancer, 2016, 57, 118-126.	1.3	5
100	Stem Cells Inhibition by Bevacizumab in Combination with Neoadjuvant Chemotherapy for Breast Cancer. Journal of Clinical Medicine, 2019, 8, 612.	1.0	5
101	Cancer stem cells: Just sign here!. Cell Cycle, 2010, 9, 227-232.	1.3	3
102	Immunohistochemical subtypes predict the clinical outcome in high-risk node-negative breast cancer patients treated with adjuvant FEC regimen: results of a single-center retrospective study. BMC Cancer, 2015, 15, 697.	1.1	3
103	What drives breast cancer heterogeneity: oncogenic events or cell of origin?. Journal of Pathology, 2012, 227, 267-269.	2.1	2
104	Computational Screening of Anti-Cancer Drugs Identifies a New BRCA Independent Gene Expression Signature to Predict Breast Cancer Sensitivity to Cisplatin. Cancers, 2022, 14, 2404.	1.7	2
105	CorrÃ©lation imagerie-anatomopathologie en biopsie mammaireÂ: utilitÃ© de la classification europÃ©enne illustrÃ©e en cas cliniques. Imagerie De La Femme, 2015, 25, 22-31.	0.0	0
106	Flick the cancer stem cells' switch to turn cancer off. Molecular and Cellular Oncology, 2017, 4, e1319896.	0.3	0
107	Genome-wide RNA interference screen in cancer stem cells. Methods in Cell Biology, 2022, , .	0.5	0